Cite
HARVARD Citation
Crittenden, M. et al. (2015). Phase I study of safety and immunogenicity of ADU-623, a live-attenuated listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRVIII and NY-ESO-1, in patients with who grade III/IV astrocytomas. Journal for immunotherapy of cancer. 3 (2), pp. 1-2. [Online].